In the second half of 2021, mergers and acquisitions in the pharmaceutical industry are still active

Since the second half of 2021, mergers and acquisitions in the domestic pharmaceutical industry have remained active.
Recently, a group of pharmaceutical companies have initiated mergers and acquisitions, including Buchang Pharmaceuticals and Yuanda Pharmaceuticals
.
Buchang Pharmaceutical intends to acquire Beijing Chengrui for 271 million yuan Buchang Pharmaceuticals announced on the evening of October 14 that the company and its wholly-owned subsidiary, Shenzhou Pharmaceutical, intends to acquire 100% of Beijing Chengrui, with a total transaction price of 271 million yuan
.
The announcement shows that the purpose of this acquisition is to meet the future business development needs of Buchang Pharmaceuticals, promote the smooth implementation of the company's overall strategy, enhance the company's overall operating environment and external image, and realize the plan of "China's Johnson & Johnson, the world's step"
.
It is worth mentioning that Buchang Pharmaceuticals previously issued a series of announcements such as the investment in the establishment of Ningbo Buchang Trading Company and the acquisition of Hunan Zhongce.
From the perspective of the industry, these are actually the embodiment of the strategic transformation of Buchang Pharmaceuticals
.
Broad Pharma intends to acquire an 80% stake in Brilliance Biosciences for 100 million yuan Broad Pharma announced on the evening of October 18 that its subsidiary Hubei Broad Life Science and Technology Co.
, Ltd.
has recently entered into an equity purchase agreement with Hebei Huayang Biotechnology Co.
, Ltd.
, and agreed to wait until relevant conditions are met.
Later, it will acquire an 80% stake in Brilliance Bio for 107.
2 million yuan
.
Broad Pharmaceutical said that this acquisition is expected to bring new business growth points to Broad Pharmaceutical's biotechnology products and health products.
It is also an important step for Broad Pharmaceutical's diversified amino acid strategy based on high-quality amino acids
.
Xingqi Eye Medicine intends to acquire the remaining 33.
2% equity of Xingqi Eye Hospital for 130 million yuan.
Xingqi Eye Medicine announced on September 30 that the company intends to acquire 33.
20% of the equity of Xingqi Eye Hospital held by Ningbo Zhensheng.
After the acquisition is completed Xingqi Eye Medicine holds a total of 100.
00% of Xingqi Eye Hospital, and Xingqi Eye Hospital will change from a holding subsidiary of the company to a wholly-owned subsidiary
.
The price of the underlying equity transfer is approximately 130 million yuan
.
Regarding this transaction, the company said that it will help to further improve the decision-making process and operational management efficiency of Xingqi Eye Hospital, which will help the company integrate resources and further optimize the shareholding structure. .
Sinovac intends to acquire CSPC Shengxue for 800 million yuan.
On July 27, Sinovac announced that the company intends to purchase 100% of its shares in CSPC Shengxue by issuing shares to its controlling shareholder Enbipu Pharmaceutical.
The issuance price of the shares to purchase assets is 11.
12 yuan per share, and the 100% equity of CSPC Shengxue is initially determined to be 800 million yuan
.
At the same time, it plans to issue shares to specific targets to raise matching funds, and the total amount of matching funds raised shall not exceed 100% of the transaction price of the assets to be purchased
.
Regarding this transaction, the company stated that it will further expand the company's health business, enhance profitability, and extend its main business upstream and downstream as one of the measures, which is conducive to the improvement of the profitability and sustainable development of listed companies
.
Yixintang acquired 56% equity of Bencaotang for 154 million yuan.
On July 10, Yixintang issued an announcement stating that Yixintang Sichuan, a wholly-owned subsidiary of the company, holds 56% equity of Bencaotang through capital increase and equity transfer, involving an amount of 1.
54.
100 million yuan
.
The completion of this acquisition means that Yixintang enters the Sichuan-Chongqing pharmaceutical retail market
.
Renhe Pharmaceuticals acquired 80% of each of the 7 companies for 719 million yuan.
On July 6, Renhe Pharmaceuticals announced that the company intends to acquire Shenzhen Sanpu Natural Cosmetics Co.
, Ltd.
, Jiangxi Juhe E-commerce Co.
, Ltd.
, and Jiangxi Juhe E-commerce Co.
, Ltd.
for 719 million yuan.
Jiangxi Juyouyou E-Commerce Co.
, Ltd.
and other 7 companies each have 80% equity, and they are deployed in the health and cosmetics industries
.
Fangsheng Pharmaceutical acquired 100% equity of Tengwangge Pharmaceutical for 176 million yuan.
On July 6, Fangsheng Pharmaceutical announced that it would acquire 100% equity of Tengwangge Pharmaceutical with its own funds of 176 million yuan
.
For this acquisition, Fangsheng Pharmaceutical stated that it is in line with the needs of the company's long-term development strategy and can greatly reduce the time required for the company's expansion
.
At the same time, it is conducive to the company's reserve of drug varieties with development potential, expanding the coverage of common diseases and commonly used drugs, and overall helping to enhance the company's profitability and improve the company's competitiveness in the industry
.